Mal/adaptations: A qualitative evidence synthesis of opioid agonist therapy during major disruptions.  Salamanca-Buentello F, Cheng DK, Sabioni P, Majid U, Upshur R, Sud A.  Int J Drug Policy. 2021 Dec 10;101:103556. doi: 10.1016/j.drugp…

The impact of COVID-19 on addiction treatment in New Zealand.  Rodda SN, Park JJ, Wilkinson-Meyers L, King DL. Addict Behav. 2021 Dec 27;127:107230. doi: 10.1016/j.addbeh.2021.107230. Epub ahead of print. PMID: 34996006; PMCID: PMC8711171. h…

Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.  Sivakumar A, Madden…

The COVID-19 pandemic and the health of people who use illicit opioids in New York City, the first 12 months.  Bennett AS, Townsend T, Elliott L.  Int J Drug Policy. 2021 Dec 1;101:103554. doi: 10.1016/j.drugpo.2021.103554. Epub ahead of…

Experiences with take-home dosing in heroin-assisted treatment in Switzerland during the COVID-19 pandemic-Is an update of legal restrictions warranted?  Meyer M, Strasser J, Köck P, Walter M, Vogel M, Dürsteler KM.  Int J Drug Policy. 2…

Implementing a Methadone Delivery System in New York City in Response to COVID-19.  Harocopos A, Nolan ML, Goldstein GP, Mantha S, O'Neill M, Paone D.  Am J Public Health. 2021 Dec;111(12):2115-2117. doi: 10.2105/AJPH.2021.306523. PMID…